

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CELLTECH R&D LTD.	07/19/2012
RECEIVING PARTY DATA	
Name:	UCB PHARMA, S.A.
Street Address:	60, ALLEE DE LA RECHERCHE
City:	BRUSSELS
State/Country:	BELGIUM
Postal Code:	B-1070
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13522087
CORRESPONDENCE DATA	
Fax Number:	3523725800
Phone:	3523758100
Email:	fce@slepatents.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	FRANK C. EISENSCHENK, PH.D.
Address Line 1:	P.O. BOX 142950
Address Line 4:	GAINESVILLE, FLORIDA 32614-2950
ATTORNEY DOCKET NUMBER:	UCB.106
NAME OF SUBMITTER:	FRANK C. EISENSCHENK, PH.D.
Total Attachments: 1 source=ExecAsgn-Cell2Ucb#page1.tif	

OP \$40.00 13522087

ASSIGNMENT FROM CELLTECH R&D LTD.
TO
UCB PHARMA, S.A.

In consideration of one dollar (\$1.00) and other good and valuable consideration, CELLTECH R&D LTD., having a place of business at 208 Bath Road, Slough SL1 3WE, Berkshire, United Kingdom, sells and assigns to UCB PHARMA, S.A., having a place of business at 60, Allée de la Recherche, B-1070 Brussels, Belgium, its successors and assigns, the entire right, title and interest throughout the world in and to the improvements in:

“Bacterial Host Strain Comprising a Mutant SPR Gene and Having Reduced TSP Activity”
U.S. Patent Application Serial No. 13/522,087, filed July 13, 2012,

and in and to said application and all patents (foreign and domestic) which may be granted therefor and thereon, and all divisions, reissues, continuations and extensions thereof (foreign and domestic), and CELLTECH R&D LTD. authorizes and requests the Commissioner of Patents and Trademarks to issue all patents on said improvements or resulting therefrom to said UCB PHARMA, S.A., as assignee of the entire interest; and it agrees that it will sign all lawful papers, execute all divisional, continuing and reissue applications, and make all rightful oaths to aid said UCB PHARMA, S.A., its successors, assigns and nominees, to obtain and enforce proper protection for said improvements in all countries.

Executed this 19 day of JULY, 2012.

CELLTECH R&D LTD.

By: [Signature]

Printed Name: S. C. JONES
Title: CEO

WITNESS:

Signature: [Signature]

Printed Name: R. GILL

Date: 19/07/12